Cryoport Inc (CYRX)

Currency in USD
10.39
-0.54(-4.94%)
Closed·
10.390.00(0.00%)
·
CYRX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
10.2810.87
52 wk Range
4.5811.45
Key Statistics
Prev. Close
10.93
Open
10.87
Day's Range
10.28-10.87
52 wk Range
4.58-11.45
Volume
324.24K
Average Volume (3m)
538.37K
1-Year Change
29.7129%
Book Value / Share
9.45
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CYRX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
13.22
Upside
+27.26%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales decline in the current year

Cryoport Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Cryoport Inc Company Profile

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company’s Life Sciences Services segment provides temperature-controlled logistics and cryogenic biostorage within the life science industry. Its Life Sciences Products segment offers cryogenic freezers, cryogenic dewars, and accessories within the life science industry through direct sales or a distribution network. The company’s products include Cryoport Express Shippers; Cryoport ELITE Shippers; Cryoport Express Cryogenic HV3 Shipping System; Smartpak II Condition Monitoring System and Tec4Med; and Cryoport accessories. It also provides Cryoport BioStorage/Bioservices, such as CRYOGENE, a biostorage solution for the provision of pre-clinical temperature-controlled biological materials management services; and Cryoport Systems Bioservices, including controlled temperature storage, kitting, labelling, fulfillment, sample management, drug return, and Qualified Person drug product release. In addition, the company offers IntegriCell services that comprise apheresis/leukapheresis collection, cryoshuttle transportation, cryo-process optimization, and cryopreservation services; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; CRYOPDP, a temperature-controlled logistics solution; MVE Biological Solutions’ Fusion cryogenic system, a self-sustaining cryogenic freezer; and Vario cryogenic system, a cryogenic freezer system. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. The company was founded in 1999 and is based in Brentwood, Tennessee.

Cryoport Inc SWOT Analysis


Cryoport's Crossroads
Explore Cryoport's strategic position in cold chain logistics, facing growth challenges amidst a declining stock price and market capitalization of $388 million
Financial Headwinds
Delve into Cryoport's revised revenue guidance and cost-cutting measures, aiming for adjusted EBITDA profitability by 2025 despite recent downward trends
Market Dynamics
Analyst targets range from $8 to $15 per share, reflecting mixed views on Cryoport's potential in the evolving cell and gene therapy secto
Future Trajectory
Learn how new FDA approvals and cost reduction initiatives could reshape Cryoport's growth prospects, balancing against ongoing challenges in key segments
Read full SWOT analysis

Cryoport Inc Earnings Call Summary for Q3/2025

  • Cryoport's Q3 2025 EPS of -$0.18 beat forecasts by 25%, with revenue of $44.23 million exceeding expectations by 7.3%, driving a 2.54% stock price increase to $9.04.
  • The company achieved positive cash flow from operations of $2.2 million and narrowed adjusted EBITDA loss to $600,000, with gross margins improving to 48%.
  • Management forecasts high single-digit growth in the MVE product segment and expects to achieve positive adjusted EBITDA by year-end 2025 or early 2026.
  • CEO Jerrell Shelton emphasized Cryoport's critical role in temperature-controlled supply chains for cell and gene therapies, with the company supporting numerous clinical trials.
  • Despite anticipated limited growth in China for 2026, the company maintains a positive outlook on commercial therapy growth with minimal regulatory risks expected.
Last Updated: 2025-11-04, 06:22 p/m
Read Full Transcript

Compare CYRX to Peers and Sector

Metrics to compare
CYRX
Peers
Sector
Relationship
P/E Ratio
−8.6x−0.3x−0.6x
PEG Ratio
−0.060.000.00
Price/Book
1.1x1.4x2.6x
Price / LTM Sales
2.1x2.5x3.4x
Upside (Analyst Target)
25.1%10.7%42.0%
Fair Value Upside
Unlock14.4%5.0%Unlock

Analyst Ratings

8 Buy
1 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 13.22
(+27.26% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Needham
Buy12.00+15.50%11.00MaintainNov 05, 2025
BTIG
Buy15.00+44.37%10.00MaintainSep 18, 2025
Leerink Partners
Buy16.00+53.99%-UpgradeAug 06, 2025
Jefferies
Hold8.00-23.00%6.50MaintainAug 06, 2025
KeyBanc
Buy15.00+44.37%-UpgradeAug 06, 2025

Earnings

Latest Release
Nov 04, 2025
EPS / Forecast
-0.18 / -0.24
Revenue / Forecast
44.23M / 41.22M
EPS Revisions
Last 90 days

CYRX Income Statement

People Also Watch

44.470
HROW
-1.88%
31.40
CMCL
+6.05%
21.500
AVDL
-0.14%
35.38
AMTM
-0.51%
36.09
GSL
-0.55%

FAQ

What Is the Cryoport Inc (CYRX) Stock Price Today?

The Cryoport Inc stock price today is 10.39

What Stock Exchange Does Cryoport Inc Trade On?

Cryoport Inc is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Cryoport Inc?

The stock symbol for Cryoport Inc is "CYRX."

What Is the Cryoport Inc Market Cap?

As of today, Cryoport Inc market cap is 520.22M.

What Is Cryoport Inc's Earnings Per Share (TTM)?

The Cryoport Inc EPS (TTM) is -1.21.

When Is the Next Cryoport Inc Earnings Date?

Cryoport Inc will release its next earnings report on Mar 11, 2026.

From a Technical Analysis Perspective, Is CYRX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Cryoport Inc Stock Split?

Cryoport Inc has split 2 times.

How Many Employees Does Cryoport Inc Have?

Cryoport Inc has 1098 employees.

What is the current trading status of Cryoport Inc (CYRX)?

As of Jan 25, 2026, Cryoport Inc (CYRX) is trading at a price of 10.39, with a previous close of 10.93. The stock has fluctuated within a day range of 10.28 to 10.87, while its 52-week range spans from 4.58 to 11.45.

What Is Cryoport Inc (CYRX) Price Target According to Analysts?

The average 12-month price target for Cryoport Inc is USD13.22, with a high estimate of USD16 and a low estimate of USD9.5. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +27.26% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.